Application of CDCA in preparation of drug for treating osteoarthritis

Abstract

The invention relates to a new application of a monomer compound CDCA, and particularly relates to the application of the CDCA in preparation of a drug for treating osteoarthritis and a drug composition for treating the osteoarthritis. The drug composition can be prepared into an injection, a tablet, a capsule, an electuary, a drop, a granule or an ointment by adding general medicinal auxiliary components to the CDCA being not less than 98% in purity. A pharmacological experiment result proves that the CDCA can significantly improve inflammatory cell infiltration, proliferation of fibrous tissue and cartilage surface damage and the like situations in an osteoarthritic location, can reduce the levels of MMP-1, MMP-3, IL-1[beta] and PGE2 in synovial fluid and has a strong osteoarthritis-resistant effect, so that the CDCA can be used for preparing a drug for treating the osteoarthritis. The invention provides a new drug source to treatment of the osteoarthritis.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to the application of CDCA in the preparation of medicines for treating osteoarthritis Background technique [0002] Osteoarthritis (OA) is a degenerative disease characterized by degeneration of articular cartilage, mainly manifested as abnormal metabolism of articular cartilage and damage to articular bone structure, leading to loss of function in severe cases. OA is more common in middle-aged and elderly people, and the onset process is mostly slow. Hands, knees, hips, and spine joints are easily involved, while metacarpophalangeal, wrist, and other joints are less involved. The disease usually aggravates with activities or relieves with rest. [0003] Osteoarthritis OA has become an important cause of loss of labor for people over 50 years old, second only to ischemic heart disease. Among them, the knee joint has the highest incidence rate, and there are about 360 million arthri...

AI Technical Summary

Problems solved by technology

[0007] As a known monomeric compound, CDCA has a definite molecular formula and structural formula, but its research activity is not high. At present, there are very few reports on the pharmacological effects of CDCA. The pharmacological research reports mainly include antitussive, antiasthma, Promote bile secretion and dissolve gallstones, clinically mainly used in the prevention and treatment of gallstone syndrome or the prevention and treatment of liver and gallbladder diseases

So far, the application of CDCA as a monomer compound in the preparation of drugs for the treatment of osteoarthritis has not been reported.

Images